Australian Clinical Labs announces takeover offer for Healius Limited

Australian Clinical Labs Limited (ASX: ACL) has announced its plan to make an off-market takeover offer to acquire all fully paid ordinary shares in Healius Limited. The offer is for 0.74 ACL shares for every 1 Healius share held and represents a nil-premium merger based on the volume weighted average price of Healius shares and ACL shares on the ASX for the period from February 28, 2023, to March 17, 2023.

 If the acquisition is successful, Healius shareholders and ACL shareholders will hold approximately 68% and 32% of ACL, respectively. This acquisition is expected to create Australia’s largest pathology provider, with more approved collection centres (ACCs) nationally than any other pathology provider in the Australian market, and expected to unlock approximately AU$95 million of annual, recurring, pre-tax cost synergies, equivalent to approximately 95% of Healius’ FY23 EBIT.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com